GLG Pharma
Why Show the GSK Compound? Because the cancer cells become resistant. How? By STAT3! GLG's Compounds Reverse Resistance
Why Show the GSK Compound? Because the cancer cells become resistant. How? By STAT3! GLG's Compounds Reverse Resistance
GLG Pharma, Inc. (GLG) is a Jupiter, Florida-based clinical-stage biotechnology company focused on developing next-generation therapies for hyper-proliferative diseases including cancer, polycystic kidney disease, psoriasis, Crohn’s disease, and inflammatory bowel disease. The company's precision medicines target the STAT3 cancer gateway and employ integrative genomics-powered cell culture platform, Gx-C3TM, for personalized therapy. GLG's unique approach involves capturing patient cells, culturing and expanding them ex-vivo in a biomimetic, three-dimensional microenvironment and systematically screening them against a proprietary library of new chemical and repurposed small molecule inhibitors. Promisingly, the company is currently involved in clinical trials for Chronic Lymphocytic Leukemia (CLL - GLG-801) and Triple Negative Breast Cancer (TNBC). Additionally, GLG-302 is part of a Cancer Prevention Program in collaboration with the National Cancer Institute. The company received a Venture Round investment on 16 October 2012 from the Florida Institute for Commercialization. For more information, visit www.glgpharma.com or contact Richard Gabriel, CEO GLG Pharma, Inc. - 781-883-6639, [email protected].
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Venture Round | Unknown | 1 |
|
16 Oct 2012 |
| Venture Round | Unknown | 1 |
|
10 May 2012 |
No recent news or press coverage available for GLG Pharma.
We care about your data, and we'd love to use cookies make your experience better.
